Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$530.31 USD
-0.08 (-0.02%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $530.07 -0.24 (-0.05%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Elevance Health (ELV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$608.84 | $649.00 | $558.00 | 13.61% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Elevance Health comes to $608.84. The forecasts range from a low of $558.00 to a high of $649.00. The average price target represents an increase of 13.61% from the last closing price of $535.92.
Analyst Price Targets (19)
Broker Rating
Elevance Health currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.16 a month ago based on 19 recommendations.
Of the 20 recommendations deriving the current ABR, 17 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 85% and 10% of all recommendations. A month ago, Strong Buy made up 89.47%, while Buy represented 5.26%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ELV.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 17 | 17 | 17 | 16 | 16 |
Buy | 2 | 2 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.16 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/18/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Strong Buy |
4/19/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/19/2024 | UBS | Aj Rice | Not Available | Strong Buy |
4/19/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/19/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
4/18/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
4/8/2024 | Wells Fargo Securities | Stephen Baxter | Strong Buy | Strong Buy |
4/4/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Gary Taylor | Strong Buy | Strong Buy |
3/27/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
3/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/6/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
2/1/2024 | Not Identified | Not Identified | Hold | Hold |
1/24/2024 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
1/24/2024 | Goldman Sachs | Nathan Rich | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 20 |
Average Target Price | $608.84 |
LT Growth Rate | 12.20% |
Industry | Medical Services |
Industry Rank by ABR | 88 of 252 |
Current Quarter EPS Est: | 9.99 |